Oxford, UK – Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and
Ridinilazole is a novel class antibiotic with potential for broad use in the treatment of CDI. In a Phase 2 clinical trial, ridinilazole showed statistical superiority over vancomycin in rates of sustained clinical response, an endpoint that captures both initial cure and recurrence of CDI.
“This new patent grant in one of our potential major commercial markets substantially strengthens our intellectual property estate protecting our novel CDI antibiotic ridinilazole and supports our efforts to maximise the potential of this promising compound,”
The patent (United States Patent 9,314,456) is entitled ‘Antibacterial Compounds’, and provides a period of exclusivity for ridinilazole in the United States until at least 1 December 2029, with the possibility of patent term extension.
|Company||Summit Therapeutics plc|